Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...
查看详情GUANGZHOU, CHINA, January 5, 2018– Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline...
Recently, the Antibody-Drug Conjugates (ADCs) program’s‘Recombinant Humanized anti-HER2 Monoclonal Antibody-Maytansine ...
On September 5 2016,Bio-thera reached a strategic cooperation agreement with world class CRO, Quintiles. Under agreement...
